| LncRNA | MiRNA | Gene | Gene name | Pathway Name | Description | Title | Disease/Tissue | Journal | PubMed ID |
| CCAT1 | miR-218 | BMI1 | BMI1；FLVI2/BMI1；PCGF4；RNF51 | details
Transcriptional misregulation in cancer
|
details
This epigenetic silencing of miR-218 by CCAT1 induces an altered cell cycle transition through BMI1 and provides a new mechanism for CSE-induced lung carcinogenesis.
|
details
Epigenetic silencing of miR-218 by the lncRNA CCAT1, acting via BMI1, promotes an altered cell cycle transition in the malignant transformation of HBE cells induced by cigarette smoke extract
|
Lung Cancer | Toxicol Appl Pharmacol | 27212446 |
| MALAT1 | miR-218 | EZH2 | EZH2；ENX-1；ENX1；EZH1；EZH2b；KMT6；KMT6A；WVS；WVS2 | details | details
EZH2 is highly expressed and associated with the 3' end region of lncRNA MALAT1 in colorectal cancer, and this association suppressed the expression of E-cadherin. Furthermore, targeted inhibition of MALAT1 or EZH2 reversed EMT and chemoresistance induced by oxaliplatin. Finally, the interaction between lncRNA MALAT1 and miR-218 was observed, which further indicated its prognostic value in patients who received standard FOLFOX (oxaliplatin combine with 5-fluorouracil and leucovorin) treatment.
|
details
MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
|
Colorectal Cancer | Mol Cancer Ther | 28069878 |